House dust mite allergy vaccine - NovozymesAlternative Names: Allergy vaccine - Novozymes
Latest Information Update: 08 Nov 2005
At a glance
- Originator Novozymes A/S
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 07 Nov 2005 Discontinued - Preclinical for Allergy in Denmark (unspecified route)
- 02 Jun 2005 The house dust mite allergy vaccine has been outlicensed
- 08 Jun 2004 Preclinical trials in Allergy in Denmark (unspecified route)